Date: 25-Oct-2019

Aurobindo Pharma gets USFDA nod for its expectorant tablets

Drug firm Aurobindo Pharma on Thursday said it has received final nod from the US health regulator for its Guaifenesin extended-release tablets used as expectorant. The company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture its generic Guaifenesin extended-release tablets in the strengths of 600 mg and 1,200 mg, Aurobindo Pharma said in a filing to the BSE. The product is expected to be launched in the fourth quarter of 2019-20, it added. The company's tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.